The Cancer Institute of New Jersey (CINJ) is a matrix style cancer center under the auspices of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. The Director serves as Associate Dean for Oncology Programs and is responsible for integrated research at the medical school with the Robert Wood Johnson University Hospital, the St. Peter's University Hospital, and several schools and departments of Rutgers University. CINJ was awarded its first P30 Cancer Support Grant (CA72720) on March 1, 1997. CINJ has 124 members, whose peer-reviewed, funded research projects, as defined by the CCSG guidelines, total more than $26.5 million in annual direct costs, over $6 million of which is from the NCI. The research base of CINJ is organized into seven programs: Cancer Pharmacology; Carcinogenesis and Chemoprevention; Molecular Mechanisms of Tumor Growth; Cytokines, Growth Factors, and Signal Transduction: Transcriptional Regulation and Oncogenesis; Clinical Investigations; and Cancer Control. With this application, CINJ has added programmatic strength in Population Science through two programs, Carcinogenesis and Chemoprevention, and Cancer Control. This application requests support for the following: Senior Leadership; Major Program Leaders; Planning and Evaluation; Developmental Funds; Administration; Clinical Protocol Scientific Review and Monitoring; and Protocol Specific Research. In addition, we are requesting funds for the following shared resources of CINJ: Analytical Cytometry; DNA Synthesis and Sequencing; Laboratory Support Services; Immunohistochemistry; Tissue Retrieval Service; Biometrics; Research Pharmacy; and Clinical Research Office.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA072720-07S2
Application #
6799846
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
2000-04-06
Project End
2005-02-28
Budget Start
2003-03-01
Budget End
2004-02-29
Support Year
7
Fiscal Year
2003
Total Cost
$400,000
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212

Showing the most recent 10 out of 775 publications